Sand Hill Global Advisors’s Novo Nordisk NVO Stock Holding History

Sand Hill Global Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,287	Closed	-$227K	–	209
2025 Q2	$227K	Buy	+3,287	New	+$224K	0.01%	188
2024 Q4	–	Sell	-1,830	Closed	-$218K	–	198
2024 Q3	$218K	Sell	1,830 -25	-1%	-$3.33K	0.01%	189
2024 Q2	$265K	Buy	+1,855	New	+$246K	0.01%	168

Other funds holding NVO

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sand Hill Global Advisors's NVO Position: Q3 2025 in Review

Sand Hill Global Advisors sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 3,287 shares — an estimated $227K sold.

Sand Hill Global Advisors first reported a position in NVO in Q2 2024 and held it in 3 quarters. The position peaked at $265K in Q2 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

Sand Hill Global Advisors reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
Sand Hill Global Advisors sold 3,287 Novo Nordisk shares in Q3 2025, an estimated $227K.
Sand Hill Global Advisors first reported a position in Novo Nordisk in Q2 2024 and held it in 3 quarters.
Sand Hill Global Advisors's Novo Nordisk position peaked at $265K in Q2 2024.
1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Sand Hill Global Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.